Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Piacentini

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
International Journal of Sports Physiology and Performance|September 6, 2017
Changes in Choice Reaction Time During and After 8 Days Exhaustive Cycling Are Not Related to Changes in Physical PerformanceTwan Ten Haaf, Selma van Staveren, Danilo Iannetta, et al.
ESMO Open|September 12, 2021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
ESMO Open|February 8, 2022
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
Breast Cancer Research and Treatment|April 5, 2017
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast (Edinburgh, Scotland)|August 15, 2022
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancerA Viansone, B Pellegrino, C Omarini, et al.
Plos One|October 31, 2018
Multi-dimensional flow cytometry analysis reveals increasing changes in the systemic neutrophil compartment during seven consecutive days of endurance exerciseSelma van Staveren, Twan Ten Haaf, Margot Klöpping, et al.
ESMO Open|February 14, 2021
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID eraA Toss, C Isca, M Venturelli, et al.
The Pharmacogenomics Journal|July 6, 2016
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancerA Musolino, N Naldi, M V Dieci, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019L Moscetti, E Barbieri, E Zattarin, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
International Journal of Sports Physiology and Performance|September 6, 2017
Changes in Choice Reaction Time During and After 8 Days Exhaustive Cycling Are Not Related to Changes in Physical PerformanceTwan Ten Haaf, Selma van Staveren, Danilo Iannetta, et al.
ESMO Open|September 12, 2021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
ESMO Open|February 8, 2022
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
Breast Cancer Research and Treatment|April 5, 2017
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast (Edinburgh, Scotland)|August 15, 2022
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancerA Viansone, B Pellegrino, C Omarini, et al.
Plos One|October 31, 2018
Multi-dimensional flow cytometry analysis reveals increasing changes in the systemic neutrophil compartment during seven consecutive days of endurance exerciseSelma van Staveren, Twan Ten Haaf, Margot Klöpping, et al.
ESMO Open|February 14, 2021
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID eraA Toss, C Isca, M Venturelli, et al.
The Pharmacogenomics Journal|July 6, 2016
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancerA Musolino, N Naldi, M V Dieci, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019L Moscetti, E Barbieri, E Zattarin, et al.
Pageof 7